Generic placeholder image

Current Enzyme Inhibition

Editor-in-Chief

ISSN (Print): 1573-4080
ISSN (Online): 1875-6662

Research Article

Relationship with Metalloproteinase 13, E-cadherin, Homocysteine and Co Factors Folic Acid and Vitamin B12 in Patients Diagnosed with Prostate Cancer

Author(s): Thaís M. Gascón*, Beatriz G. Lourenço, Edimar C. Pereira, Beatriz A. da Costa Aguiar, Glaucia L. Veiga, Flavia de Sousa Gehrke, Fernando Adami and Fernando L.A. Fonseca

Volume 17 , Issue 1 , 2021

Published on: 26 October, 2020

Page: [33 - 41] Pages: 9

DOI: 10.2174/1573408016999201026195354

Price: $65

Abstract

Introduction: Prostate cancer (Pc) is the most frequent neoplasia in men and the second cause of death in Brazil.

Objective: To analyze the interactions and biologicals responses of Pc oxidative stress and prostatespecific antigen (PSA), E-cadherin and MMP-13. Demonstrate whether the increase of the amount of the form of E-cadherin found in the plasma of Pc patients, correlates with decrease of the PSA.

Methods: Samples were obtained through peripheral venipuncture to analyse parameters of biomarkers pc as PSA, E-cadherin, MMP-13, Homocysteine, Folic acid, Vitamin B12, Testosterone T and free following the patients diagnosis, 3 and 6 months during their treatment to analyze the biological responses of Pc oxidative stress.

Results: The analysis was performed by using immunoenzymatic assay. Statistical data processed through Excel in Windows Vista and analyzed through the Shapiro-wilk Test, ANOVA, and Spearman Test. An increase in the concentration of E-cadherin (p = 0.02), as a decrease in concentration of PSA (p < 0.001), total testosterone (p < 0.001) and free testosterone (p = 0.02) was observed during the treatment period without significant alterations in the remaining markers for either of the periods.

Discussion: It was found that during treatment of men diagnosed with pc that there was an an increase in the concentration of plasmatic E-cadherin, which was negatively correlated with the concentrations of folic acid (-0,03 (0,87) rs (p). It was observed that the levels of hcy are positively correlated with concentrations of total testosterone and a negative correlation. Vitamins B12 remained within the parameters of normality during the entire study.

Conclusion: P.S.A levels were free and total testosterone levels decreased. In this way, monitoring the folic acid, E-cadherin dosages of patients during the treatment phases can effectively complement in the face of remission, since it would be a way of preventing abnormal cell replications, with a clinical view prudent so that the cell methylation cycle is not affected.

Keywords: Prostate cancer, metalloproteinase-13, E-cadherin, homocysteine, biomarkers, prostate-specific antigen.

Graphical Abstract
[1]
Kowalczyk, A.P.; Nanes, B.A. Adherens junction turnover: regulating adhesion through cadherin endocytosis, degradation, and recycling. Subcell. Biochem., 2012, 60, 197-222.
[http://dx.doi.org/10.1007/978-94-007-4186-7_9] [PMID: 22674073]
[2]
Li, Y.; Tollefsbol, T.O. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr. Med. Chem., 2010, 17(20), 2141-2151.
[http://dx.doi.org/10.2174/092986710791299966] [PMID: 20423306]
[3]
INCA-Instituto Nacional de Câncer. 2018.http://www.inca.gov.br/estimativa/2018/referencias.asp
[4]
Paz, A.P.E.; Guimarães, M.R.; Muzi, D.C. Análise da tendência da mortalidade masculina no Rio de Janeiro: Contribuição da enfermagem. Esc Anna Nery.ed., 2014, 18(4), 593-599.
[5]
Walter, S.H.; Ahmed, S. Targeted therapies in cancer. Cancer Treatment. Surgery; Published by Elsevier Ltd, 2017, 36(3)
[6]
Oh, B.; Figtree, G.; Costa, D. Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate Int., 2016, 4, 71-87.https://DOI.org/10.1016/j.prnil.2016.05.002
[http://dx.doi.org/10.1016/j.prnil.2016.05.002]
[7]
Stabler, S.; Koyama, T.; Zhao, Z.; Martinez-Ferrer, M.; Allen, R.H.; Luka, Z.; Loukachevitch, L.V.; Clark, P.E.; Wagner, C.; Bhowmick, N.A. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One, 2011, 6(8)e22486
[http://dx.doi.org/10.1371/journal.pone.0022486] [PMID: 21853037]
[8]
Silva, T.C.; Jasiulionis, G.M. Relação entre estresse oxidativo, alterações epigenéticas e câncer., 2014, 66, 2317-6660.
[http://dx.doi.org/10.21800/S0009-67252014000100015]
[9]
Hultdin, J.; Van Guelpen, B.; Bergh, A.; Hallmans, G.; Stattin, P. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: A prospective study. Int. J. Cancer, 2005, 113(5), 819-824.
[http://dx.doi.org/10.1002/ijc.20646] [PMID: 15499634]
[10]
Tonon, A. Prostate cancer: A literature review. Health Res Magazine, 2009, 2(3), 403-410.
[11]
Dini, L.I.; Koff, W.J. Profile of prostate cancer at the clinic hospital in Porto Alegre. Rev. Assoc. Med. Bras. (1992), 2006, 52(1), 28-31.
[http://dx.doi.org/10.1590/S0104-42302006000100018] [PMID: 16622535]
[12]
Kleer, C.G.; van Golen, K.L.; Braun, T.; Merajver, S.D. Persistent E-cadherin expression in inflammatory breast cancer. Mod. Pathol., 2001, 14(5), 458-464.
[http://dx.doi.org/10.1038/modpathol.3880334] [PMID: 11353057]
[13]
Wang, Z.R.; Chen, H.; Gao, S.S.; Qiu, H.; Li, H.W.; Sun, Z.L.; Wang, J.M. Implications of soluble E-cadherin level of antiviral treatment in patients with chronic hepatitis C virus infection. Int. Immunopharmacol., 2019.74105708
[http://dx.doi.org/10.1016/j.intimp.2019.105708] [PMID: 31254956]
[14]
Wong, M.H.S.; Fang, M.C.; Chuah, H.L. E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit. Rev. Oncol. Hematol., 2018, 121, 11-22.https://DOI.org/10.1016/j.critrevonc.2017.11.010
[15]
Drivalos, A.; Chrisofos, M.; Efstathiou, E. Expression of α5-integrin, α7-integrin, Ε-cadherin, and N-cadherinin localized prostate cancer. Urologic Oncology: Seminarsand Original Investigations, 2016, 165, e11-165-e18,34.
[16]
Padmanaban, V.; Krol, I.; Suhail, Y. E-cadherin is required for metastasis in multiple models of breast cancer. Nature, 2019, 573(7774), 439-444.
[17]
Kim, N.H.; Kim, S.N.; Kim, Y.K. Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion. Biochem. Biophys. Res. Commun., 2011, 404(4), 915-921.
[http://dx.doi.org/10.1016/j.bbrc.2010.12.081] [PMID: 21184735]
[18]
Brasileiro Filho, G. Growth disorders and cell differentiation. In: Bogliolo pathology. Rio de Janeiro, Guanabara Koogan, 7th ed; , 2006; pp. 181-204.
[19]
Egeblad, M. Egeblad M: The role of metrix metalloproteinase 13 in breast cancer. Postdoctoral Fellowship (Cycle VII); Unversity of California, San Francisco, 2002.
[20]
Rodríguez, D.; Morrison, C.J.; Overall, C.M. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta, 2010, 1803(1), 39-54.
[http://dx.doi.org/10.1016/j.bbamcr.2009.09.015] [PMID: 19800373]
[21]
Gascón, M.T.; Schindler, F. Avaliação do Método de Quimioluminescência na análise de homocisteína plasmática e sua comparação com o método de HPLC em amostras de crianças; Revista Einstein, 2010.
[22]
Cambruzzi, E.; Zettler, G.C.; Pegas, L.K. Relação entre escore de Gleason e fatores prognósticos no adenocarcinoma acinar de próstata. Bras. Patol. Med. Lab., 2010, 46(1), 61-68.
[http://dx.doi.org/10.1590/S1676-24442010000100011]
[23]
Diretrizes Diagnósticas e Terapêuticas do Adenocarcinoma de Próstata. Relatório de Recomendação., http://conitec.gov.br/2018
[24]
Reis, B.R.; Cassini, F.M. Antígeno Prostático Específico (P.S.A). Urologia fundamental. Cap., 2010, 2, 190-194.
[25]
Giltay, E.J.; Hoogeveen, E.K.; Elbers, J.M.; Gooren, L.J.; Asscheman, H.; Stehouwer, C.D. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J. Clin. Endocrinol. Metab., 1998, 83(2), 550-553.
[http://dx.doi.org/10.1210/jcem.83.2.4574] [PMID: 9467573]
[26]
Claps, M.; Petrelli, F.; Caffo, O.; Amoroso, V.; Roca, E.; Mosca, A.; Maines, F.; Barni, S.; Berruti, A. Testosterone levels and prostate cancer prognosis: Systematic review and meta-analysis. Clin. Genitourin. Cancer, 2018, 16(3), 165-175.e2.
[http://dx.doi.org/10.1016/j.clgc.2018.01.005] [http://dx.doi.org/10.1016/j.clgc.2018.01.005] [PMID: 29454638]
[27]
Collin, S.M.; Metcalfe, C.; Refsum, H.; Lewis, S.J.; Smith, G.D.; Cox, A.; Davis, M.; Marsden, G.; Johnston, C.; Lane, J.A.; Donovan, J.L.; Neal, D.E.; Hamdy, F.C.; Smith, A.D.; Martin, R.M. Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer. Cancer Epidemiol. Biomarkers Prev., 2010, 19(11), 2833-2838.
[http://dx.doi.org/10.1158/1055-9965.EPI-10-0582] [PMID: 20852008]
[28]
Keshteli, H.A.; Baracos, V.; Madsen, K. Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: A review. World J. Gastroenterol., 2015, 21(4), 1081-1090.
[http://dx.doi.org/10.3748/wjg.v21.i4.1081]
[29]
Martínez-Poveda, B.; Chavarría, T.; Sánchez-Jiménez, F.; Quesada, A.R.; Medina, M.A. An in vitro evaluation of the effects of homocysteine thiolactone on key steps of angiogenesis and tumor invasion. Biochem. Biophys. Res. Commun., 2003, 311(3), 649-653.
[http://dx.doi.org/10.1016/j.bbrc.2003.10.044] [PMID: 14623320]
[30]
Mariano, C.; Steluti, J.; Marchioni, L, M. The vitamins and minerals related to genomic stability and cancer protection. Nutrire: rev. Soc. Bras. Alim. Nutr. J. Brazilian Soc. Food Nutr., São Paulo, SP, 2010, 35(2), 181-199.
[31]
Bonaldi, C.M.; Azzalis, L.A.; Junqueira, V.B.; de Oliveira, C.G.; Vilas Boas, V.A.; Gáscon, T.M.; Gehrke, F.S.; Kuniyoshi, R.K.; Alves, B.C.; Fonseca, F.L. Plasma levels of E-cadherin and MMP-13 in prostate cancer patients: correlation with PSA, testosterone and pathological parameters. Tumori, 2015, 101(2), 185-188.
[http://dx.doi.org/10.5301/tj.5000237] [PMID: 25733385]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy